A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 14, 2016

Primary Completion Date

December 21, 2017

Study Completion Date

December 21, 2017

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

Faster-acting insulin aspart

A single dose administered subcutaneously (s.c., under the skin). The dose level will be 0.3 U/kg body weight.

DRUG

Insulin Aspart

A single dose administered subcutaneously (s.c., under the skin). The dose level will be 0.3 U/kg body weight.

Trial Locations (1)

Novo Nordisk Investigational Site, Graz